◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound SKIP-FOR-NOW HIGH

Anadrol

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict SKIP-FOR-NOW HIGH

"SKIP-AT-20 with maximum confidence for a 20-year-old MMA athlete + business owner. Anadrol is the worst-fit AAS in the entire SKIP-AT-20 cluster for this archetype because (1) it produces the most severe hepatotoxicity of any commonly-used oral AAS — the Hengge/Schroeder 2003 Phase 3 trial documented that 27-35% of subjects on 100-150 mg/day developed ALT elevation >5× ULN within 16 weeks, and case series document peliosis hepatis, hepatic adenoma, and hepatocellular carcinoma in chronic users; (2) its paradoxical estrogenicity (gynecomastia + water retention despite zero aromatization) means standard AI-based estrogen management fails — only SERMs (tamoxifen, raloxifene) work, and the gyno risk is among the highest of any AAS; (3) the cardiovascular load is severe — HDL crashes 50-80% within weeks, BP rises sharply, hematocrit can exceed 55%, and the combination produces a meaningful acute MI/stroke risk profile poorly suited to MMA training cardiac demands; (4) for an MMA athlete with peak endogenous testosterone (~600-900 ng/dL at age 20), no documented hypogonadism, and a multi-decade competitive arc ahead, the post-cycle hypogonadism + persistent hypothalamic-pituitary-testicular dysfunction risk (Rasmussen 2016) trades 4-6 weeks of supraphysiologic mass for years of recovery; (5) Anadrol shows up on every WADA, USADA, IBJJF, NCAA, and most state athletic commission tested-list — career-ending for any tested combat athlete. Verdict reverses ONLY for the same medical indication clusters that justify ANY 17αAA — severe AIDS-wasting cachexia, severe aplastic anemia, Fanconi anemia, severe burn (>40% TBSA) — none of which apply. There is no recreational, performance, or aesthetic use case under which Anadrol is the right tool for this archetype: oxandrolone (Anavar) has a substantially milder hepatic profile for cutting; methandrostenolone (Dianabol) provides similar mass with somewhat lower per-mg liver hit; injectable testosterone esters dominate for foundational anabolic effect at a fraction of the hepatic burden. Anadrol's only competitive niche is \"fastest oral mass + strength gain in 4-6 weeks\" — and that niche is dominated by other tools at every other axis. Verdict applies universally for under-25 brain-priority athletes; would not change with V4/V5 stack optimization, genetics results, or training context."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, high cognitive workload + MMA athlete (this archetype)
    SKIP-AT-

    No coherent use case. Brain-priority profile explicitly avoids HPG-axis suppressors at age 20. Anadrol is the most aggressive HPG suppressor + highest hepatotoxicity oral AAS. Aesthetic/anabolic goals are downstream priorities. Combat-sport tested status (USADA, IBJJF, state athletic commissions) makes detection career-ending. Even setting aside regulatory risk, oxandrolone or methandrostenolone provide better risk:benefit at the recreational anabolic axis, and injectable T dominates for foundational anabolic effect. The fastest-mass-gain niche Anadrol fills is satisfied by a combination of training optimization + creatine + V4/V5 stack at 0% biological cost.

  • 30-50, executive maintenance
    SKIP-PERMANENT

    Modern TRT (transdermal or injectable testosterone) handles physiological androgen replacement cleanly. Recreational Anadrol use risks dominate any benefit.

  • 50+, mild cognitive decline / sarcopenia
    SKIP-PERMANENT

    TRT-indicated population uses transdermal/injectable T. Anadrol's hepatotoxicity is especially poor fit for an aging liver with reduced reserve. Aplastic anemia or Fanconi anemia are the only legitimate Rx contexts.

  • Anxiety-prone
    SKIP-PERMANENT

    Mood/aggression profile is among the worst of any AAS. Sleep disruption common. Hostile combination.

  • High athletic load, tested status
    SKIP-PERMANENT

    Detection windows 6-8 weeks. WADA S1.1a banned. Career-ending for any tested combat athlete.

  • High athletic load, untested status (relevant adjacent profile)
    SKIP-AT-

    specifically; OPTIONAL-WITH-CAVEATS at 25+ for advanced AAS users. Even for advanced untested users, Anadrol's hepatic and cardiovascular profile is among the worst of any AAS. Most experienced users prefer oxandrolone for cutting, methandrostenolone for bulking, and injectable T as foundation. Anadrol's specific niche — fastest oral mass kickstart in 4 weeks — is real but rarely worth the risk profile.

  • Sleep-disordered
    SKIP-PERMANENT

    Polycythemia + sleep apnea exacerbation + BP elevation + cortisol disruption.

  • Recovery-focused (post-injury, post-illness)
    SKIP-PERMANENT

    Hepatic load on a recovering body is wrong direction. Oxandrolone (Oxandrin) has FDA-approved burn/post-trauma indication; Anadrol does not in any modern non-anemia context.

  • Strength/anabolic-focused
    SKIP-AT-

    The fastest-strength-curve niche is real but among the worst hepatic risk:benefit. Methandrostenolone + injectable T provides similar results with substantially lower cost.

  • Severe medical wasting / aplastic anemia / Fanconi anemia
    CONDITIONAL-USE

    under hematologist supervision. This is the legitimate medical indication. FDA-approved label still active. Mortality benefit demonstrated in bone-marrow-failure populations. Universal verdict for this archetype: SKIP-AT-20, HIGH confidence, applies universally. No realistic conditions flip the verdict for a 20-year-old MMA athlete with peak endogenous testosterone, no medical wasting indication, and combat-sport career arc ahead.

▸ Subjective experience (deep)

Onset: Rapid. Within 24-72 hours at 50 mg/day, most users report:

  • Increased aggression / drive
  • Increased appetite ("Anadrol hunger")
  • Joint warmth and joint puffiness from water retention
  • "Pumped" sensation even at rest
  • Mood elevation or irritability

Week 1-2: "The Anadrol week-one experience" is famous in bodybuilding culture. 5-10 lb scale gain (mostly water + glycogen). Pronounced strength curve — multi-rep PRs jump significantly. Subjective sense of being "filled out" or "thick." Paired with: rapid water-driven blood pressure elevation, possible headaches, possible sleep disruption.

Week 2-4: Strength curve continues steeply. LBM begins to add. Skin starts to break out (acne — direct AR effect). Hair shedding may accelerate in users with androgenic-alopecia susceptibility. Liver enzyme rise typically becomes detectable in this window if checked. HDL begins crashing. Hematocrit climbs.

Week 4-6: Plateau onset. Continued mass accumulation slows; water retention may increase further. Liver enzyme elevations often peak in this window. Some users develop early-stage gynecomastia (nipple sensitivity, "tickling" sensation, palpable nodule) — this is the urgent sign to discontinue and add tamoxifen 20 mg/day.

Week 6-8 (if continued past common ceiling): Diminishing returns vs. accelerating side-effect profile. Cholestatic symptoms possible (RUQ pain, dark urine, pruritus, jaundice). Most experienced users discontinue by week 6 maximum to avoid cumulative hepatic damage.

Discontinuation: Rapid water-mediated weight loss within 1-2 weeks (5-10 lb water shed). HPG suppression already established — testicular atrophy, low endogenous T, impaired libido for 8-16 weeks. PCT (clomiphene 25-50 mg/day or enclomiphene 12.5-25 mg/day) standard for 4-6 weeks. Liver enzymes typically normalize within 8-12 weeks of discontinuation. Lipid profile recovery slower, often 12-24 weeks for HDL to fully rebound.

Characteristic effects vs other oral AAS:

  • More water retention than dianabol; far more than oxandrolone (which is non-aromatizable and dry)
  • More aggression than dianabol; comparable to trenbolone
  • More gynecomastia risk than any other oral AAS (uncontrollable by AIs — only SERMs work)
  • Worse LFT impact than dianabol; substantially worse than oxandrolone
  • Larger raw mass gains in 4-6 weeks than any other oral; primary "bulker oral"

Honest variability: Substantial. AR sensitivity polymorphism (CAG repeat length) drives 2-3× variance in response. Liver-injury susceptibility varies — some users tolerate full 6-week courses with mild LFT bumps; others develop cholestasis at week 2-3. Users with shorter AR CAG repeats (more responsive AR) may experience more dramatic gains AND more dramatic side effects.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Anabolic effect plateaus at 4-6 weeks. AR receptor downregulation modest. Liver toxicity is cumulative — cycling does not "reset" hepatic burden; each cycle adds incremental hepatocellular stress.
  • Recommended cycle: Don't. If used despite recommendation, 4 weeks max at 50 mg/day with mandatory hepatoprotection (TUDCA 500-1000 mg/day, NAC 1.2-2.4 g/day, milk thistle 600 mg silymarin extract daily) and weekly LFT. Maximum cycle length 6 weeks; 4 weeks is the prudent ceiling.
  • Reset protocol (PCT): Standard PCT cascade — clomiphene 50/50/25/25 mg over 4 weeks OR enclomiphene 12.5-25 mg/day for 4-6 weeks OR tamoxifen 20/20/10/10 mg over 4 weeks. HCG 500 IU 2× weekly during cycle helps maintain testicular volume but does not prevent post-cycle hypogonadism. LFTs typically normalize within 8-12 weeks of discontinuation; lipids 12-24 weeks; HPG axis 12-24 weeks. Peliosis lesions may persist or progress independently of discontinuation.
  • Re-cycling: Strongly discouraged. Each cycle adds cumulative hepatic burden. The "blast and cruise" model that some users adopt with Anadrol is among the most hepatotoxic recreational AAS protocols possible.
▸ Stacking deep dive

Synergistic with (legitimate medical context only)

  • Injectable testosterone enanthate/cypionate (300-500 mg/week, "TRT base") — Standard bodybuilding pairing. The injectable T provides foundational androgen (preventing complete HPG-driven androgen crash during the cycle) while Anadrol provides rapid mass kickstart. Reduces oral-only burden but does not reduce Anadrol's hepatic toll.
  • HCG (250-500 IU 2× weekly during cycle) — Maintains testicular volume / Leydig responsiveness; eases PCT.
  • Liver protection stack: TUDCA 500-1000 mg/day, NAC 1.2-2.4 g/day, milk thistle 600 mg silymarin extract/day, choline 500 mg/day. Mandatory if running Anadrol despite recommendation. Reduces but does not eliminate hepatic injury risk.
  • SERM during cycle: Tamoxifen 10-20 mg/day OR raloxifene 60 mg/day — Required for Anadrol-driven gyno control because AIs don't work (Anadrol doesn't aromatize but binds ER directly). This is unique to Anadrol and a few other AAS — most cycles use AI, not SERM, during cycle.

Avoid stacking with

  • Other 17α-alkylated AAS (oxandrolone, stanozolol, methandrostenolone, methyltestosterone, fluoxymesterone, danazol) — Additive hepatotoxicity. Stacking two oral 17αAA is one of the most hepatotoxic things a recreational AAS user can do. Anadrol on top of any other oral is a particularly poor combination.
  • Aromatase inhibitors (anastrozole, letrozole) — Mechanically ineffective for Anadrol gyno (because Anadrol doesn't aromatize); may crash systemic E2 from background T conversion, producing low-E2 symptoms (joint pain, libido crash, lipid worsening). Use SERM instead.
  • Alcohol — Dramatically additive hepatic load. Avoid entirely during cycle.
  • Acetaminophen/paracetamol at therapeutic dose — Additive hepatotoxicity. Use ibuprofen for acute pain control if absolutely necessary, but minimize.
  • Statins — Additive lipid disruption + hepatic load. Notable because the lipid crash from Anadrol may prompt a statin script in poorly-counseled users — that compounds the hepatic problem.
  • NSAIDs (chronic) — Renal + hepatic compounding; additive BP load; relevant for combat athletes who often use chronic NSAIDs for joint/training pain.
  • Modafinil / adrafinil / other prodrugs with hepatic processing — Additive hepatic load.
  • Hormonal contraceptives, HRT (in female partners co-managed contexts) — Not directly relevant to user but worth noting for partnered scenarios.
  • Nephrotoxic compounds in MMA dehydration cuts (high-dose creatine + dehydration + AAS) — Synergistic kidney stress in already androgen-strained kidneys.

Neutral / safe co-administration

  • V4/V5 stack supplements — Mostly mechanistically neutral. NAC and milk thistle would be doing double duty as hepatoprotectants. Magnesium, vitamin D, omega-3, creatine — neutral. Caffeine — neutral but watch BP.
  • Most CNS nootropics (modafinil, racetams, citicoline, magnesium, alpha-GPC) — No direct mechanism interaction; modafinil shares hepatic metabolism (above).
  • Russian peptides (Semax, Selank, Bromantane) — No interaction.
  • TRT (already on testosterone for confirmed hypogonadism) — TRT base is the standard companion; this is the legitimate medical context where Anadrol might be added for short bridge.
▸ Drug interactions deep dive
  • Warfarin / anticoagulants — Oxymetholone potentiates warfarin (↑INR), risk of hemorrhage. Documented and clinically significant — warfarin dose typically requires reduction during oxymetholone therapy.
  • Insulin / oral hypoglycemics — AAS improve insulin sensitivity; may require dose reduction in diabetics. Hemodialysis-dependent patients on oxymetholone showed improved insulin sensitivity (PMID 19356374).
  • Hormonal contraceptives, HRT — Competing hormonal pathways; unpredictable effects; oxymetholone may reduce contraceptive efficacy.
  • CYP3A4/CYP2C9 substrates — Minor effects reported; clinically modest.
  • Hepatotoxic drugs (statins, isoniazid, methotrexate, valproate, acetaminophen, kava, amiodarone) — Strongly additive. Avoid co-administration where possible.
  • Levothyroxine — Possible TBG-mediated alteration in thyroid status assessment.
  • Erythropoietic agents (epoetin alfa, darbepoetin) — Compounding polycythemia risk via parallel mechanism.
  • Antihypertensives — May require dose escalation due to oxymetholone-driven BP elevation.
▸ Pharmacogenomics
  • AR CAG repeat polymorphism — Shorter CAG repeats = higher AR transcriptional activity; users with shorter repeats may be more responsive to anabolic effects (and side effects) at lower dose. CAG ~21 average; range 9-37. Relevant for response prediction once 23andMe data is available (~June 2026).
  • CYP3A4/3A5 polymorphism — CYP3A5 expressers (~10% of Caucasians) may clear oxymetholone modestly faster. Effect minor.
  • HLA-B alleles — Unspecified subset may predispose to drug-induced liver injury (DILI) from 17α-alkylated androgens. No specific allele identified for oxymetholone but the class effect is established.
  • UGT2B17 deletion — ~10% of Caucasians; affects testosterone glucuronidation pathway. Largely irrelevant for oxymetholone-specific clearance because oxymetholone bypasses native T metabolism.
  • For this archetype: 23andMe results pending June 2026. Even with maximally favorable polymorphisms, the catastrophic hepatic profile and HPG suppression are structural class effects, not pharmacogenomic issues. Genetics will not rescue this molecule for a 20-year-old combat athlete.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (Anadrol-50, Alaven Pharmaceutical) Specialty pharmacy via hematologist or HIV clinician $700-1500/month at 100 mg/day High where prescribable Almost never prescribed for non-anemia indications. Aplastic anemia, Fanconi anemia, severe AIDS-wasting are the realistic Rx pathways. PA (prior authorization) required by virtually all insurers.
Compounding pharmacy Limited US compounding Variable Medium-Low Not commonly compounded; FDA does not list oxymetholone on the standard compounding pharmacopeia for non-FDA indications. Limited gray-zone access.
International pharmacy (Asian / Eastern European) Various $50-200 per 50-100 tabs at 50 mg Low-Medium Anadrol generic equivalents (Anapolon by Galenika; Plenastril historically; various Indian and Chinese generics) accessible via international online pharmacies. Quality variable. Customs interception risk.
Underground lab (UGL) International unlicensed manufacturers $40-80 per 100 tabs at 50 mg Low — variable purity, mislabeling common Active 2010s-2020s recreational bodybuilding supply. Common purity issues: under-dosed (cost-cutting), substituted (dianabol or methyl-1-testosterone instead), or contaminated. Lab testing services (Janoshik, AnaboLab) recommended for any UGL product.
"Research chemical" vendor (online) Various Variable Low Some vendors market oxymetholone as "research chem" exploiting regulatory gray zones. Quality and identity verification critical.
Veterinary N/A N/A N/A Not a veterinary drug; not available through veterinary supply.

Bottom line on sourcing for this archetype: No legitimate pathway. Modern medical use is limited to a small population of hematology and HIV cases. Recreational sourcing requires international pharmacy access or UGL with all attendant quality risks. For a 20-year-old MMA athlete + business owner, every viable sourcing path involves either (a) regulatory risk (DEA Schedule III possession), (b) tested-status risk (USADA/IBJJF/state athletic commission detection), or (c) supply-chain quality risk (UGL contamination, mislabeling, dosing errors). There is no clean sourcing path for this archetype.

▸ Biomarkers to track (deep)

If used despite the SKIP recommendation (medical indication only):

Baseline (before starting)

  • Liver: ALT, AST, GGT, alkaline phosphatase, total + direct bilirubin, albumin, PT/INR, hepatitis B/C serology
  • Lipids: Total cholesterol, LDL-C, HDL-C, ApoB, triglycerides, Lp(a)
  • Hormonal: Total + free testosterone, SHBG, estradiol (sensitive assay), LH, FSH, prolactin, DHT
  • CBC: Hematocrit, hemoglobin, RBC, WBC, platelets
  • Renal: Creatinine, eGFR, cystatin C, BUN, urinalysis (protein, blood)
  • Cardiac: Resting BP, ECG; echocardiogram baseline if extended use planned (chronic AAS users develop LV hypertrophy)
  • Hepatic imaging: Baseline abdominal ultrasound for liver/biliary architecture
  • Glycemic: HbA1c, fasting glucose, fasting insulin
  • Tactile chest/breast exam for baseline gynecomastia status

During use

  • Week 2: full LFT, BP — stop drug if ALT/AST >3× ULN, bilirubin >2× ULN, or symptoms (jaundice, RUQ pain, pruritus, dark urine, marked BP elevation)
  • Week 4: full LFT, lipid panel, CBC, BP, gyno tactile exam — monitor cholestatic markers, HDL nadir, HCT trajectory, breast tissue
  • Week 6: full LFT, lipid, hormonal panel, BP, gyno exam — last data point in standard 4-6 week cycle
  • HCT >54% = stop drug, consider therapeutic phlebotomy
  • Any palpable breast nodule = stop drug, add tamoxifen 20 mg/day

Post-cycle

  • Week 4 post: LFT, lipid, hormonal panel, CBC, BP, gyno exam
  • Week 12 post: LFT, lipid, hormonal panel — confirm normalization
  • Week 24 post: hormonal panel — full HPG recovery timepoint; PCT decision
  • Annual abdominal ultrasound for users with extended exposure (peliosis surveillance)
▸ Controversies / open debates Live debate

1. The "non-aromatizing yet estrogenic" paradox mechanism

  • Pavlatos 2001 hypothesis: Direct ER binding/activation by oxymetholone itself (SERM-like ER agonism in breast tissue)
  • Alternative hypothesis: Weak progesterone receptor activity (analogous to nandrolone progestogenic gyno)
  • Alternative hypothesis: Mineralocorticoid receptor activity (parallel to fludrocortisone-like fluid retention)
  • Status: Unresolved. Multiple mechanisms may contribute. Practical implication is identical regardless of mechanism — AIs don't work, SERMs do. The mechanistic question is academic for clinical management but matters for designing future AAS that retain anabolic potency without estrogenicity.

2. Hengge/Schroeder 2003 dose-finding: was the 100 mg/day finding adequately powered to claim equivalence with 150 mg/day?

  • Argument for equivalence: Both arms produced statistically significant weight gain vs. placebo; 100 mg arm had less ALT elevation; weight gain numerically similar.
  • Argument against: N=89 split across three arms may be underpowered for non-inferiority claim. Some bodybuilders extrapolate this to "100 mg/day is the optimal dose" — that's an over-reading.
  • Practical implication: 50-100 mg/day is the realistic effective range; 100 mg/day is the sensible ceiling; 150 mg/day adds toxicity without meaningful additional benefit per the available data.

3. "Anadrol is safer than people think because the FDA-approved label uses it"

  • Argument: FDA-approved active label = FDA accepts the safety profile in indicated populations.
  • Counter: FDA-approved indication is for severe bone-marrow failure where mortality risk dominates hepatotoxicity risk. The risk-benefit ratio is entirely different in healthy bodybuilders.
  • Practical implication: FDA approval does not imply general safety; it implies indication-specific acceptable risk.

4. "TUDCA + NAC + milk thistle make Anadrol safe"

  • Argument: Modern hepatoprotective stacking dramatically reduces LFT abnormalities during cycles.
  • Counter: Hepatoprotective stacks reduce transaminase elevation but do not address the structural-injury mechanisms (cholestasis, peliosis hepatis, adenoma). The reduction in measurable LFTs may give a false sense of safety while the underlying tissue damage continues.
  • Practical implication: Hepatoprotectants are harm-reduction, not safety. Cumulative cycle exposure still adds long-term risk.

5. The "blast and cruise" model with Anadrol as recurring blaster

  • Argument: Some advanced users repeatedly use Anadrol as a 4-week "blaster" several times per year on top of TRT cruise.
  • Counter: This is among the most hepatotoxic recreational protocols possible. Cumulative hepatic burden compounds across cycles regardless of inter-cycle washout.
  • Practical implication: Not recommended. Single-cycle exposure is the prudent ceiling if Anadrol is used at all.

6. Female use historically vs modern

  • Historical: Anadrol was occasionally used by female bodybuilders in the 1980s-1990s for off-season mass.
  • Modern: Almost universally abandoned by female athletes due to severe virilization risk (vocal cord thickening, clitoral hypertrophy, body hair distribution shift — all irreversible). Oxandrolone has displaced it for women.
  • Practical implication: Female use of Anadrol is not appropriate in 2026 — virilization risk dominates any benefit.
▸ Verdict change log
  • 2026-05-10 — Initial verdict: SKIP-AT-20 / HIGH CONFIDENCE / THOROUGH research pass. Anadrol is the highest-hepatotoxicity oral AAS in common use, with profound HPG suppression, paradoxical estrogenicity (uncontrollable by AIs), and a cardiovascular load (HDL crash, BP elevation, polycythemia, LV hypertrophy risk) explicitly hostile to a multi-decade combat-sports career. For a 20-year-old MMA athlete + business owner with peak endogenous testosterone and brain-priority orientation, no recreational use case wins for Anadrol over oxandrolone (cutting), methandrostenolone (bulking), or injectable testosterone (foundation). Verdict reverses only for severe medical wasting / aplastic anemia / Fanconi anemia under specialist supervision. Verdict applies universally across user profiles in the under-25 brain-priority cluster.
▸ Open questions / gaps Open

  1. Mechanism of Anadrol's paradoxical estrogenicity. Pavlatos 2001 ER-direct-activation hypothesis is leading but not definitively confirmed. PR / MR contributions unclear. Resolution would matter for designing next-generation AAS without estrogenic burden but doesn't change present clinical management.

  2. Long-term hepatic outcomes in modern bodybuilders using Anadrol with hepatoprotective stacks. No prospective cohort study exists. Most data is from 1970s-1980s case reports (peliosis, adenoma, HCC) when hepatoprotective use was uncommon. Modern incidence with TUDCA/NAC/milk thistle stacking unknown but mechanism suggests reduction, not elimination, of risk.

  3. Optimal Anadrol cycle length for harm reduction. 4 weeks vs 6 weeks vs 8 weeks — no dose-finding study has formally addressed where the inflection point of cumulative hepatic burden lies. Prudent ceiling is 4-6 weeks per bodybuilding tradition + Hengge/Schroeder data, but the underlying biology is not well-characterized.

  4. Pharmacogenomic predictors of Anadrol-induced DILI. HLA-B alleles relevant to drug-induced liver injury have been identified for other agents (e.g., abacavir, flucloxacillin) but no Anadrol-specific predictor exists. Would be high-value research for the indicated medical populations (Fanconi anemia, aplastic anemia chronic users).

  5. Combination Anadrol + GH/IGF-1 in bone-marrow failure. Some Fanconi anemia protocols pair oxymetholone with GH; mechanism-additive but not formally trial-validated.

  6. Modern Anadrol substitutes. SARMs (RAD-140, MK-2866, LGD-4033) have been marketed as "Anadrol alternatives" but have their own hepatotoxicity signal and are themselves WADA-banned. No clean alternative exists for the legitimate medical wasting indications outside the established AAS class. For recreational anabolic effect, oxandrolone or injectable testosterone esters remain the dominant cleaner alternatives.

References

Hengge UR et al. 2003 — Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting (AIDS)

pubmed.ncbi.nlm.nih.gov · 2003

landmark Phase 3 RCT establishing efficacy + 27-35% ALT >5× ULN safety signal

View Study

Schroeder ET et al. 2003 — Oxymetholone for the treatment of HIV-wasting: a double-blind, randomized, placebo-controlled phase III trial in eugonadal men and women (companion analysis)

pubmed.ncbi.nlm.nih.gov · 2003

eugonadal subgroup confirming additive anabolic effect on top of normal endogenous T

View Study

Hengge UR et al. 1996 — Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection (British Journal of Nutrition)

pubmed.ncbi.nlm.nih.gov · 1996

pilot study foundation for the Phase 3 trial

View Study

Pavlatos AM et al. 2001 — Review of oxymetholone: a 17α-alkylated anabolic-androgenic steroid (Clinical Therapeutics)

pubmed.ncbi.nlm.nih.gov · 2001

reference review; articulates the non-aromatizing-yet-estrogenic paradox and proposes direct ER activation

View Study

Zhang QS et al. 2014 — Oxymetholone therapy of Fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling (Stem Cell Reports)

pubmed.ncbi.nlm.nih.gov · 2014

extends FDA-approved Fanconi indication mechanistic understanding

View Study

Anadrol-50 (oxymetholone) FDA label, Alaven Pharmaceutical

accessdata.fda.gov

current US label, indications, dosing

View Source

Anabolic Steroids — LiverTox NCBI Bookshelf NBK548931

ncbi.nlm.nih.gov

class entry on AAS hepatotoxicity; oxymetholone Likelihood A

View Source

Kanayama G, Pope HG Jr — Long-term cardiovascular consequences of AAS (Am J Cardiol)

pubmed.ncbi.nlm.nih.gov

cardiomyopathy literature

View Source

Vanberg P, Atar D 2010 — Androgenic anabolic steroid abuse and the cardiovascular system (Handbook of Experimental Pharmacology)

link.springer.com · 2010

CV mechanism review

View Source

DEA Diversion Control: Anabolic Steroids

deadiversion.usdoj.gov

Schedule III status, federal regulation

View Source

Latest research

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…